贝伐珠单抗与卡铂组合方案对卵巢癌患者血清TGF-β_(1)、HDGF、MIF的影响  

Effect of Bevacizumab combined with Carboplatin on serum TGF-β_(1),HDGF and MIF in patients with ovarian cancer

作　　者：刘品一[1] 杨海祥 Liu Pinyi;Yang Haixiang(Department of Oncology,Baotou Central Hospital ofInner Mongolia Autonomous Region,Baotou 014040,China)

机构地区：[1]内蒙古自治区包头市中心医院肿瘤内科,内蒙古包头014040

出　　处：《实用妇科内分泌电子杂志》2022年第15期11-13,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探讨卵巢癌患者予以贝伐珠单抗与卡铂组合方案联合治疗对血清转化生长因子-β_(1)(TGF-β_(1))、肝细胞癌衍生生长因子(HDGF)及巨噬细胞移动抑制因子(MIF)的影响。方法选取卵巢癌患者68例为研究对象,根据随机数字表法分为对照组与研究组,每组34例。对照组给予卡铂治疗,研究组在对照组基础上予以贝伐珠单抗治疗。比较治疗前后患者血清TGF-β_(1)、HDGF及MIF水平以及治疗效果、不良反应情况。结果治疗前,两组患者血清TGF-β_(1)、HDGF及MIF水平比较,差异无统计学意义(P>0.05);治疗后,两组TGF-β_(1)、HDGF、MIF水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。研究组治疗有效率高于对照组,不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论贝伐珠单抗与卡铂组合方案联合治疗卵巢癌可改善患者血清TGF-β_(1)、HDGF、MIF水平,减少不良反应,疗效显著,值得临床推广与应用。Objective To investigate the effects of Bevacizumab combined with Carboplatin on serum transforming growth factor-β_(1)(TGF-β_(1)),hepatocellular carcinoma derived growth factor(HDGF)and macrophage migration inhibitory factor(MIF)in patients with ovarian cancer.Methods Sixty-eight patients with ovarian cancer were randomly divided into control group and study group,34 cases in each group.The control group was treated with Carboplatin,and the study group was treated with Bevacizumab on the basis of the control group.The levels of serum TGF-β_(1),HDGF and MIF,treatment effects and adverse reactions were compared before and after treatment.Results Before treatment,there was no significant difference in serum TGF-β_(1),HDGF and MIF levels between the two groups(P>0.05).After treatment,the levels of TGF-β_(1),HDGF and MIF in the two groups were lower than those before treatment,and the study group was lower than the control group,and the differences were statistically significant(P<0.05).The effective rate of the study group was higher than that of the control group,and the incidence of adverse reactions was lower than that of the control group,and the differences were statistically significant(P<0.05).Conclusion The combined regimen of Bevacizumab and Carboplatin in the treatment of ovarian cancer can improve the serum levels of TGF-β_(1),HDGF and MIF,reduce adverse reactions,and has significant efficacy which is worthy of clinical promotion and application.

关 键 词：卵巢癌 卡铂 贝伐珠单抗 不良反应 肿瘤标志物 

分 类 号：R737.31[医药卫生—肿瘤]